Moreover, we confirmed that CSPG4-CAR-T cells retain their cytolytic capacity towards decitabine-treated SKOV-3 ovarian cancer cells in the presence of 1 μM decitabine enabling a simultaneous application of CAR-T cells together with decitabine in the clinical setting (Supplementary Figure S2c). The gene discussed is CSPG4; the disease is ovarian carcinoma.